Delving into the Latest Updates on Hangzhou Yirui Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Skin and Musculoskeletal Diseases

Congenital Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

Ion channels	2
Kv1.3(Voltage-gated potassium channel subunit Kv1.3)	1
GPCR(G-protein coupled receptor)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

IND Application

Phase 2 Clinical

1

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YR-001 ( Kv1.3 )	Dermatitis, Atopic More	Phase 2
CP-001(Hangzhou Yirui Pharmaceutical Technology)	Erectile Dysfunction More	IND Application
YR-101 ( Ion channels )	Diabetic Nephropathies More	Preclinical
YR-201 ( GPCR )	Retinal Diseases More	Preclinical
YR-002 ( Ion channels )	Pruritus More	Preclinical